COVID-19 and Methylene Blue

Dear Editor, I would like to comment on the article "COVID-19 should be a methylene blue "promoter"^[1]". Evora noted that "I decided to resubmit the letter now, considering that COVID-19 should be a methylene blue 'promoter', and the dye can get the lifesaving status it deserves ^[1]." In fact, the use of classic available agent as a possible therapeutic agent for the emerging COVID-19 should be supported. It is better than do nothing. Many classic drugs such as hydroxychloroquine are proposed and tested for managing COVID-19^[2]. At the moment, we have to take the risk of a new alternative proposal for the treatment of COVID-19 such as convalescent plasma therapy^[3]. Using a safe and well-known agent might not have a confirmation for its efficacy but we have many data on its safety, and it might be a good alternative option compared to a totally unknown new alternative.

REFERENCES

• ¹ Evora PRB. COVID-19 should be a methylene blue "promoter". Braz J Cardiovasc Surg. 2020;35(4):604-5. doi:10.21470/1678-9741-1-2020-0607.
  » https://doi.org/10.21470/1678-9741-1-2020-0607
• ² Joob B, Wiwanitkit V. Evidence of protective effect of hydroxychloroquine on COVID-19. J Rheumatol. 2020;47(10):1587. doi:10.3899/jrheum.200638.
  » https://doi.org/10.3899/jrheum.200638
• ³ Wiwanitkit V. Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence. Int J Surg. 2020;80:26. doi:10.1016/j.ijsu.2020.06.029.
  » https://doi.org/10.1016/j.ijsu.2020.06.029

Publication Dates

• Publication in this collection
  22 Feb 2021
• Date of issue
  Jan-Feb 2021